Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CD123-directed chimeric antigen receptor T-cell (CART123) therapy for relapsed/refractory pediatric acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLucy CainDBDiane BaniewiczJFJoseph A. Fraietta

Discussion

Loading...

Member takes

Overview

Phase I clinical trial evaluates CART123 therapy in pediatric AML, showing toxicity and minimal residual disease effects.

Key Points

  • Assess the safety and efficacy of CART123 in pediatric patients with relapsed/refractory AML.
  • Single infusion of CART123 after lymphodepleting chemotherapy in pediatric patients
  • Evaluated toxicity, including cytokine release syndrome and minimal residual disease
  • CART123 expansion assessed in peripheral blood by quantitative PCR
  • 100% of patients at lower dose experienced cytokine release syndrome
  • One patient achieved MRD-negative complete response after higher dose
  • Patient showed cytokine elevation and required treatment for toxicity following infusion

Cite This Study

Cain et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e46fhttps://doi.org/10.1182/blood-2025-1643
View Full Paper
Ask AI
Bookmark
Share